June 2, 2021 10:51 AM EDT
Pharma

Lock­ing horns with Ab­b­Vie, J&J boasts post-TNF da­ta for next-gen drug Trem­fya in pso­ri­at­ic arthri­tis

Kyle Blankenship

In a bat­tle of gi­ants, J&J and Ab­b­Vie have locked horns for years with their com­pet­ing IL-23 drugs, both look­ing to take the helm as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

FDA de­fends in­creased use of guid­ance in new re­port to Con­gress

Sanofi ear­marks €1B for new in­sulin pro­duc­tion fac­to­ry in Bei­jing   

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Agenus launch­es bi­o­log­ics man­u­fac­tur­ing busi­ness to gen­er­ate cash

A service from the Financial Times